Would you like to participate ask a question join the surfers in our next episode?

S2-E57.1 – 2021 TLMdX from AASLD: Putting a “Big, Fat Dent” in NAFLD and NASH

Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on, in the words of Stephen Harrison, "putting a big, fat dent in Fatty Liver disease."

Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on what we have learned about NITs and clinical development testing that will, in the words of Stephen Harrison, “put a big, fat dent in Fatty Liver disease.”

The conversation starts with the group congratulating Manal Abdelmalek on her wrap-up NAFLD talk at TLMdX 2021. From there, the group focuses on the shortcomings of using biopsy as the clinical trial gold standard and how strategic clinical trial design and interpretation of existing NIT data can build a bridge from biopsy through MRE/biopsy correlations to a total NIT future.

Request Transcript of This Episode
Request Transcript
First
Last